Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xuanzhu Biopharmaceutical CoHKSE:02575 +3.21%11 Piotroski F-Score is 7 as of Aug. 10, 2026, which is at its 10-year median of 7.00. GuruFocus rates HKSE:02575 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 977 Drug Manufacturers companies, Xuanzhu Biopharmaceutical Co ranks better than 91.91% on this metric.
Good Sign:
Piotroski F-Score is 7, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Xuanzhu Biopharmaceutical Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Xuanzhu Biopharmaceutical Co's Piotroski F-Score or its related term are showing as below:
HKSE:02575'
s Piotroski F-Score Range Over the Past 10 Years
Min: 7 Med: 7 Max: 7
Current: 7
During the past 3 years, the highest Piotroski F-Score of Xuanzhu Biopharmaceutical Co was 7. The lowest was 7. And the median was 7.
Xuanzhu Biopharmaceutical Co (HKSE:02575) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Xuanzhu Biopharmaceutical Co Piotroski F-Score Related Terms
Xuanzhu Biopharmaceutical Co Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xuanzhu Biopharmaceutical Co Piotroski F-Score Chart
Xuanzhu Biopharmaceutical Co Annual Data
Trend
Dec23
Dec24
Dec25
Piotroski F-Score
N/A
N/A
7.00
Xuanzhu Biopharmaceutical Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Piotroski F-Score
N/A
0.00
N/A
0.00
7.00
HKSE:02575 vs ZTS: Piotroski F-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Xuanzhu Biopharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xuanzhu Biopharmaceutical Co Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xuanzhu Biopharmaceutical Co's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Xuanzhu Biopharmaceutical Co's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Xuanzhu Biopharmaceutical Co's current Net Income (TTM) was -271.22.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Xuanzhu Biopharmaceutical Co's current Cash Flow from Operations (TTM) was -231.95.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Xuanzhu Biopharmaceutical Co's return on assets of this year was -0.21228916. Xuanzhu Biopharmaceutical Co's return on assets of last year was -0.41116193.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Xuanzhu Biopharmaceutical Co's gearing of this year was 0. Xuanzhu Biopharmaceutical Co's gearing of last year was 0.00050762.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Xuanzhu Biopharmaceutical Co's current ratio of this year was 3.7531365. Xuanzhu Biopharmaceutical Co's current ratio of last year was 2.05842429.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Xuanzhu Biopharmaceutical Co's number of shares in issue this year was 464.819. Xuanzhu Biopharmaceutical Co's number of shares in issue last year was 517.948.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Xuanzhu Biopharmaceutical Co's gross margin of this year was 0.64454313. Xuanzhu Biopharmaceutical Co's gross margin of last year was 0.5480066.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Xuanzhu Biopharmaceutical Co's asset turnover of this year was 0.04476686. Xuanzhu Biopharmaceutical Co's asset turnover of last year was 0.02223763.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
1
+
1
+
1
+
1
+
1
+
1
=
7
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Xuanzhu Biopharmaceutical Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
Xuanzhu Biopharmaceutical Co (HKSE:02575) has a Piotroski F-Score of 7 as of Aug. 10, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Xuanzhu Biopharmaceutical Co and its competitors. This is near median its historical median of 7.00. Over the past decade, Xuanzhu Biopharmaceutical Co's Piotroski F-Score has ranged from 7.00 to 7.00. According to the industry distribution chart, Xuanzhu Biopharmaceutical Co ranks #79 out of 977 companies in the Drug Manufacturers industry, placing it in the top 8.1%.
Is Xuanzhu Biopharmaceutical Co's Piotroski F-Score too high?
Xuanzhu Biopharmaceutical Co's current Piotroski F-Score of 7 is near median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 7.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Xuanzhu Biopharmaceutical Co's value of 7 is 40% above this industry median. Based on the distribution chart, Xuanzhu Biopharmaceutical Co ranks #79 out of 977 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Xuanzhu Biopharmaceutical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Xuanzhu Biopharmaceutical Co's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Xuanzhu Biopharmaceutical Co ranks #79 out of 977 companies for Piotroski F-Score. This places Xuanzhu Biopharmaceutical Co in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Xuanzhu Biopharmaceutical Co's value of 7 is 40% above this benchmark. Historically, Xuanzhu Biopharmaceutical Co's own Piotroski F-Score has ranged from 7.00 to 7.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, Xuanzhu Biopharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 977 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xuanzhu Biopharmaceutical Co's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Xuanzhu Biopharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xuanzhu Biopharmaceutical Co's current Piotroski F-Score is 7, which is near median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xuanzhu Biopharmaceutical Co stock overvalued right now?
Xuanzhu Biopharmaceutical Co (HKSE:02575) has a current Piotroski F-Score of 7. The current Piotroski F-Score is 7, which is near median its 10-year median of 7.00 and 40% above the Drug Manufacturers industry median of 5.00. Xuanzhu Biopharmaceutical Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Xuanzhu Biopharmaceutical Co (HKSE:02575), the current Piotroski F-Score is 7 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xuanzhu Biopharmaceutical Co Ltd is an innovation-driven biopharmaceutical company in China, leveraging its understanding of China's pharmaceutical industry and insights of its clinical needs to improve patient health and life. It has over ten drug assets under active development covering digestive diseases, oncology, and NASH. Its track record also includes the successful development of four drug candidates that were subsequently transferred and/or out-licensed to pharmaceutical companies. Its pipeline is staggered and complementary in structure, covering both validated targets with druggability as well as new mechanisms of action and drug modalities, established therapeutic areas such as oncology, and high-growth potential therapeutic areas such as NASH.
11GF Score
Get the complete analysis for HKSE:02575
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02575 has been successfully added to your 
